Veterinary Evidence最新文献

{"title":"For horses undergoing general anaesthesia, are rope recoveries or free recoveries better?","authors":"Ffion Lloyd, P. Murison","doi":"10.18849/ve.v6i3.451","DOIUrl":"https://doi.org/10.18849/ve.v6i3.451","url":null,"abstract":"PICO question \u0000In horses undergoing general anaesthesia, does assistance with ropes result in better recoveries when compared to no assistance (‘free’ recovery)? \u0000  \u0000Clinical bottom line \u0000Category of research question \u0000Treatment \u0000The number and type of study designs reviewed \u0000One randomised, non-blinded controlled trial and two retrospective cohort studies \u0000Strength of evidence \u0000Weak \u0000Outcomes reported \u0000The three studies reviewed arrive at different conclusions regarding the utility of rope assistance in recovery from general anaesthesia in horses, but examine very different populations. The randomised controlled trial provides weak evidence that rope assistance can shorten recovery and improve recovery quality in healthy (American Society of Anesthesiologists (ASA) I–II) horses. One retrospective cohort study provides weak evidence that rope assistance confers a reduction in fatality in both healthy and sick horses. The other retrospective cohort study provides weak evidence that rope assistance confers no benefit to horses undergoing emergency colic surgery. Both assisted and unassisted groups in each study had fatalities and all studies reported complications related to the rope recovery system \u0000Conclusion \u0000Insufficient evidence is available to permit a full recommendation regarding rope assistance during recovery from general anaesthesia in horses. Rope assistance may improve recovery time and quality in some horses. The decision to perform a rope-assisted recovery must be made considering individual patient, team and clinic factors. Rope assistance cannot prevent fatalities in recovery \u0000  \u0000How to apply this evidence in practice \u0000The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. \u0000Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care. \u0000  \u0000","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128395140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do papillomaviruses cause feline cutaneous squamous cell carcinoma?","authors":"Alexander Teh, M. Krockenberger","doi":"10.18849/ve.v6i3.402","DOIUrl":"https://doi.org/10.18849/ve.v6i3.402","url":null,"abstract":"PICO question \u0000In cats infected with papillomavirus, is the risk of developing feline cutaneous squamous cell carcinoma greater than cats that are not infected with papillomavirus? \u0000  \u0000Clinical bottom line \u0000Category of research question \u0000Risk \u0000The number and type of study designs reviewed \u0000Eleven papers were critically reviewed, nine were case-control studies and two were experimental in vitro studies \u0000Strength of evidence \u0000Moderate \u0000Outcomes reported \u0000Infection of feline epithelial skin cells with Felis catus papillomavirus type 2 (FcaPV-2) is a risk factor for the development of feline cutaneous squamous cell carcinoma. The pathogenesis of FcaPV-2 infection and neoplastic transformation into malignant cells shares similar pathways to the human papillomavirus (HPV) model of pathogenesis and carcinogenesis with some differences \u0000Conclusion \u0000In conclusion, there is moderate strength of evidence in the literature to support a role of FcaPV-2 in the development of cutaneous squamous cell carcinomas in cats. Therefore, prevention of infection with FcaPV-2 should prevent some cancers \u0000  \u0000How to apply this evidence in practice \u0000The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. \u0000Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care. \u0000  \u0000","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130035857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does turkey tail as an adjuvant therapy improve the quality of life of canine lymphoma patients?","authors":"J. Tong","doi":"10.18849/ve.v6i3.403","DOIUrl":"https://doi.org/10.18849/ve.v6i3.403","url":null,"abstract":"PICO question \u0000In canine lymphoma, does the supplement of turkey tail (Trametes versicolor) as an adjuvant therapy lead to a better quality of life than those that do not? \u0000  \u0000Clinical bottom line \u0000Category of research question \u0000Treatment \u0000The number and type of study designs reviewed \u0000One prospective case series was critically appraised \u0000Strength of evidence \u0000Very weak \u0000Outcomes reported \u0000The case series assessed appetite and activity level of the canine lymphoma patients. They also measured gastrointestinal toxicity and the incidence of neutropenia \u0000Conclusion \u0000This prospective case series is insufficient to support the use of turkey tail to enhance the quality of life of canine lymphoma patients. A controlled study is required to evaluate whether the use of turkey tail supplement is useful \u0000  \u0000How to apply this evidence in practice \u0000The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. \u0000Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care. \u0000  \u0000","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124221329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trilostane monitoring in canine hyperadrenocorticism: can basal cortisol replace the ACTH stimulation test?","authors":"Dr Tsouloufi, Ioannis L Oikonomidis","doi":"10.18849/ve.v6i3.412","DOIUrl":"https://doi.org/10.18849/ve.v6i3.412","url":null,"abstract":"PICO question \u0000In dogs with hyperadrenocorticism that are being treated with trilostane, does the measurement of basal cortisol levels have comparable diagnostic performance to the adrenocorticotropic hormone (ACTH) stimulation test? \u0000  \u0000Clinical bottom line \u0000Category of research question \u0000Diagnosis (effectiveness of treatment monitoring) \u0000The number and type of study designs reviewed \u0000Four cross-sectional diagnostic accuracy studies were critically reviewed \u0000Strength of evidence \u0000Weak to moderate (level 2) \u0000Outcomes reported \u0000There is evidence of moderate strength suggesting that basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane can be a good test to exclude adrenal oversuppression, while its use is not suggested for diagnostic confirmation of oversuppression. There is evidence of weak strength that basal cortisol might be helpful for identifying dogs with inadequate adrenal suppression, but cannot be used to rule it out \u0000Conclusion \u0000Although the evaluation of the available evidence is difficult due to its heterogeneity, there is moderate evidence that a basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane dose can be a good test to rule out adrenal oversuppression, but that it cannot be used to definitively diagnose oversuppression. The current evidence suggests that basal cortisol is less useful for identification of inadequate control. Based on one included study, neither ACTH-stimulated nor basal cortisol levels correlate optimally with the actual clinical response of the patient. In this context, it can be concluded that none of the currently used laboratory tests should be used as a sole monitoring tool in dogs with hyperadrenocorticism receiving trilostane and thus, the assessment of the clinical response is of utmost importance \u0000  \u0000How to apply this evidence in practice \u0000The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. \u0000Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"16 5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128831463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are glucocorticoids or NSAIDs effective in idiopathic feline urinary tract disease signs than no treatment or placebo?","authors":"L. Sofyan","doi":"10.18849/ve.v6i3.439","DOIUrl":"https://doi.org/10.18849/ve.v6i3.439","url":null,"abstract":"PICO question \u0000In cats with idiopathic feline urinary tract disease (FLUTD), are glucocorticoid or non-steroidal anti-inflammatory drugs more effective than placebo or no treatment in reducing clinical signs attributable to cystitis? \u0000  \u0000Clinical bottom line \u0000Category of research question \u0000Treatment \u0000The number and type of study designs reviewed \u0000Three randomised controlled trials have examined the efficacy of prednisolone or non-steroidal anti-inflammatory drugs (NSAIDs) in reducing the clinical signs of feline lower urinary tract disease compared to a placebo whilst one retrospective cohort study compared the reoccurrence of FLUTD in cats treated with meloxicam and without meloxicam \u0000Strength of evidence \u0000Weak \u0000Outcomes reported \u0000One small controlled trial compared prednisolone to a placebo and found no clinical differences in dysuria, microscopic haematuria, and occult blood for cats diagnosed with idiopathic non-obstructive feline lower urinary tract disease (FLUTD) hospitalised for 10 days. The study however had a very small sample size. Furthermore, the external validity of the study to similar patients discharged to their home environment is unclear. \u0000The second small controlled trial compared meloxicam to a placebo in cats diagnosed with obstructive FLUTD. Statistical analysis was applied to determine if there were significant differences in voiding behaviour, general demeanour, haematuria, food intake and abdominal pain as assessed by the veterinarians in charge during hospitalisation and owners at discharge. No statistically significant differences (P>0.05) were calculated between the two treatment groups based on the owner questionnaire and veterinarian assessment but small samples in each treatment probably limited statistical power. \u0000The third small controlled trial compared the reoccurrence of feline idiopathic cystitis (FIC), related clinical signs and recurrent urinary obstruction in cats at 10 days, 1, 2 and 6 months after discharge when treated with phenoxybenzamine and alprazolam, with or without the addition of meloxicam. No statistically significant differences were found in the reoccurrence of obstructed or non-obstructed FIC for cats treated with either meloxicam or no meloxicam. However, full details of each intervention group were not sufficient to assess for balance of prognostic factors, subjective scoring of clinical signs was not detailed, and the study was underpowered for the actual obstruction rates reported. \u0000The fourth paper was a retrospective cohort study that examined the association of different treatment factors with 30 days reobstruction. The study found no significant association between the use of meloxicam and the rate of reobstruction but a number of confounders were present \u0000Conclusion \u0000Three small randomised controlled trials and a single retrospective cohort study failed to find a significant association between the use of glucocorticoids or NSAIDs with severity of FLUTD clinical signs or risk of reo","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116263850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin choice in feline diabetes mellitus","authors":"Yaiza Gomez Mejias","doi":"10.18849/ve.v6i3.407","DOIUrl":"https://doi.org/10.18849/ve.v6i3.407","url":null,"abstract":"PICO question \u0000In cats with diabetes mellitus, do protamine zinc insulin (PZI) and glargine show a similar effect in reducing clinical signs and hypoglycaemia episodes? \u0000  \u0000Clinical bottom line \u0000Category of research question \u0000Treatment \u0000The number and type of study designs reviewed \u0000The number and type of study designs that were critically appraised was one. This study was a non-randomised retrospective trial. A systematic review was also found, which analyses the influence of insulin in diabetic remission \u0000Strength of evidence \u0000Weak \u0000Outcomes reported \u0000Compared to PZI, using glargine in recently diagnosed diabetic cats fed exclusively an ultra-low carbohydrate-high protein canned diet, may result in lower fructosamine and mean 12 hour blood glucose concentrations as well as less episodes of hypoglycaemia \u0000Conclusion \u0000In view of the strength of evidence and the outcomes from the study the following conclusion is made: in cats with diabetes mellitus where currently licensed insulin fails to result in a good glycaemic control, glargine may be considered \u0000  \u0000How to apply this evidence in practice \u0000The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. \u0000Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care. \u0000  \u0000","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"71 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116892629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tail docking and castrating lambs: does the administration of local anaesthetic or meloxicam reduce the pain response exhibited?","authors":"Evangeline Dunthorne","doi":"10.18849/ve.v6i3.462","DOIUrl":"https://doi.org/10.18849/ve.v6i3.462","url":null,"abstract":"PICO question \u0000In healthy lambs, does the administration of local anaesthetic reduce the pain response after castration and tail docking compared to the administration of meloxicam? \u0000  \u0000Clinical bottom line \u0000Category of research question \u0000Treatment \u0000The number and type of study designs reviewed \u0000Three prospective randomised clinical trials (RCT) and one clinical trial without stated randomisation were critically reviewed \u0000Strength of evidence \u0000Moderate to strong evidence in terms of their experimental design due to having three RTCs which are all relatively recent research. However, their implementation is moderate to weak as they fail to prove the hypothesis \u0000Outcomes reported \u0000In all four studies there was improvement in the pain related behaviours post administration of anaesthesia or analgesia. There is conflicting evidence on meloxicam’s efficacy, but this could be a result of time spent observing outcomes, which relates to the drugs onset of action and time of peak concentration. Lidocaine has consistently shown a reduction in acute abnormal behaviours irrespective of equipment used \u0000Conclusion \u0000Based on the studies appraised in this Knowledge Summary there is not enough evidence to determine whether local anaesthesia is more effective than meloxicam at reducing the pain exhibited by lambs undergoing castration or tail docking. It has been shown that the use of local anaesthesia in the form of injectable lidocaine will reduce acute pain displayed during marking but there remains conflicting evidence for meloxicam with likely benefits occurring after several hours \u0000  \u0000How to apply this evidence in practice \u0000The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. \u0000Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care. \u0000  \u0000","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128843899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should doses exceeding 0.2 mg/kg of oral meloxicam be given to reduce surgical recovery time in rabbits and should twice daily administration be considered?","authors":"Eleanor Best","doi":"10.18849/VE.V6I3.372","DOIUrl":"https://doi.org/10.18849/VE.V6I3.372","url":null,"abstract":"PICO question \u0000In reducing surgical recovery time in rabbits (Oryctolagus cuniculus), should doses exceeding 0.2 mg/kg of oral meloxicam be given and is twice daily administration more effective than a single daily dose? \u0000  \u0000Clinical bottom line \u0000Category of research question \u0000Treatment \u0000The number and type of study designs reviewed \u0000Nine papers were critically reviewed, yet no studies were found to directly investigate the effects of twice daily dosing with meloxicam postoperatively in rabbits. There were five descriptive, non-comparative case series; two nonblinded parallel group randomised control trials; one blinded, placebo-controlled parallel group randomised trial and one prospective, randomised crossover trial \u0000Strength of evidence \u0000Weak \u0000Outcomes reported \u0000The current recommended oral dose of meloxicam in rabbits of 0.2–0.3 mg/kg once a day was consistently described as inadequate for postoperative analgesia following surgery (Delk et al., 2014). Instead, higher doses of 1–1.5 mg/kg were required to reach a similar peak plasma concentration as found to be clinically effective in other species, such as canines, and provide a better degree of analgesia in rabbits (Montoya et al., 2004; and Delk et al., 2014). Although no studies were found evaluating twice daily administration of meloxicam, the available evidence suggests a dose exceeding 0.2–0.3 mg/kg daily is required for adequate postoperative analgesia in rabbits. Whether this increased dose could be given twice daily should be investigated, providing scope for future research \u0000Conclusion \u0000Further studies are required to directly assess the benefits of twice daily oral meloxicam. However, it is possible that a dose exceeding 0.2–0.3 mg/kg is required and therefore higher doses should be considered in these studies \u0000  \u0000How to apply this evidence in practice \u0000The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. \u0000Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care. \u0000  \u0000","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128412937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to: Does UK licensed NSAID administration reduce signs of postoperative pain in calves castrated without local anaesthesia?","authors":"Alexandra Bartlett","doi":"10.18849/ve.v6i3.525","DOIUrl":"https://doi.org/10.18849/ve.v6i3.525","url":null,"abstract":"The original version of the article has been corrected, please see the full text for details of the correction.","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"218 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134430102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of EMLA™ cream for reducing pain associated with venepuncture in felines","authors":"Erina Leask","doi":"10.18849/VE.V6I3.456","DOIUrl":"https://doi.org/10.18849/VE.V6I3.456","url":null,"abstract":"PICO question \u0000In adult cats undergoing a venepuncture procedure, does the application of a topical lidocaine based anaesthetic to the skin at the venepuncture site reduce the severity of signs associated with pain when compared to no topical anaesthetic? \u0000  \u0000Clinical bottom line \u0000Category of research question \u0000Treatment \u0000The number and type of study designs reviewed \u0000Four papers were critically reviewed. Three were prospective, double-blind, randomised, controlled clinical trials, and one was a prospective, double-blind, controlled experimental trial \u0000Strength of evidence \u0000Moderate \u0000Outcomes reported \u0000The application of Eutectic Mixture of Local Anaesthetics (EMLA™) cream to clipped skin over the procedure site, a minimum of 30 minutes prior to the venepuncture procedure, significantly reduced the severity of pain-associated behaviours during jugular phlebotomy in healthy, conscious feline patients when compared to a placebo1,2. In felines sedated with dexmedetomidine and either methadone or nalbuphine, the administration of EMLA™ cream to clipped skin for 20 minutes significantly decreased the severity of pain responses during intravenous (IV) cephalic vein catheterisation when compared to no treatment3. In clinically unwell feline patients, the use of EMLA™ cream on clipped skin at the site of jugular catheterisation 60 minutes prior demonstrated reduced pain responses compared to a placebo, but further investigation with a larger sample size is required to verify statistical significance4 \u0000Conclusion \u0000The available evidence moderately supports the hypothesis that EMLA™ cream is an effective and noninvasive treatment for providing enhanced pain-relief during jugular and cephalic vein phlebotomy for the purposes of blood collection and catheterisation, respectively. The areas for treatment should be clipped free of hair, and the cream applied for a minimum of 30 minutes in non-sedated cats and 20 minutes in cats sedated with dexmedetomidine and either methadone or nalbuphine. Moreover, when applied to normal, intact skin and covered by an occlusive bandage to avoid ingestion, it is well supported by supplementary evidence that EMLA™ cream has a wide safety margin for topical use in cats4,5 \u0000  \u0000How to apply this evidence in practice \u0000The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. \u0000Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care. \u0000  \u0000","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"70 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123456318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}